- Home
- PMN vs LSTA Comparison
PMN vs LSTA Comparison
Compare PMN & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMN
- LSTA
- Stock Information
- Founded
- PMN 2004
- LSTA 1980
- Country
- PMN Canada
- LSTA United States
- Employees
- PMN N/A
- LSTA N/A
- Industry
- PMN Pharmaceuticals and Biotechnology
- LSTA Misc Health and Biotechnology Services
- Sector
- PMN Health Care
- LSTA Health Care
- Exchange
- PMN Nasdaq
- LSTA Nasdaq
- Market Cap
- PMN 23.9M
- LSTA 20.0M
- IPO Year
- PMN N/A
- LSTA N/A
- Fundamental
- Price
- PMN $0.75
- LSTA $2.22
- Analyst Decision
- PMN Strong Buy
- LSTA Strong Buy
- Analyst Count
- PMN 1
- LSTA 1
- Target Price
- PMN $6.00
- LSTA $15.00
- AVG Volume (30 Days)
- PMN 26.2K
- LSTA 9.4K
- Earning Date
- PMN 05-13-2025
- LSTA 05-08-2025
- Dividend Yield
- PMN N/A
- LSTA N/A
- EPS Growth
- PMN N/A
- LSTA N/A
- EPS
- PMN 0.11
- LSTA N/A
- Revenue
- PMN N/A
- LSTA $1,000,000.00
- Revenue This Year
- PMN N/A
- LSTA N/A
- Revenue Next Year
- PMN N/A
- LSTA N/A
- P/E Ratio
- PMN $6.87
- LSTA N/A
- Revenue Growth
- PMN N/A
- LSTA N/A
- 52 Week Low
- PMN $0.62
- LSTA $2.05
- 52 Week High
- PMN $2.61
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- PMN 42.22
- LSTA 47.00
- Support Level
- PMN $0.63
- LSTA $2.31
- Resistance Level
- PMN $0.76
- LSTA $2.46
- Average True Range (ATR)
- PMN 0.05
- LSTA 0.15
- MACD
- PMN 0.00
- LSTA 0.02
- Stochastic Oscillator
- PMN 40.94
- LSTA 58.33
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.